|Title||SRI-286, a thiosemicarbazole, in combination with mefloquine and moxifloxacin for treatment of murine Mycobacterium avium complex disease. |
|Publication Type||Journal Article |
|Year of Publication||2004 |
|Authors||Bermudez, LE, Kolonoski, P, Seitz, LE, Petrofsky, M, Reynolds, R, Wu, M, Young, LS |
|Journal||Antimicrobial agents and chemotherapy |
|Date Published||2004 Sep |
Treatment of Mycobacterium avium disease remains challenging when macrolide resistance develops. We infected C57 beige mice and treated them with mefloquine, SRI-286, and moxifloxacin. SRI-286 (80 mg/kg) was bactericidal in the liver. Mefloquine plus moxifloxacin or mefloquine plus SRI-286 were better than mefloquine alone.